The immunodominant influenza matrix t cell epitope recognized in human induces influenza protection in HLA-A2/Kb transgenic mice

Virology

Volumn 309, Issue 2, 2003, Pages 320-329

  Plotnicky, H ^a   Cyblat Chanal, D ^a   Aubry, J P ^a   Derouet, F ^a   Klinguer Hamour, C ^a   Beck, A ^a   Bonnefoy, J Y ^a   Corvaїa, N ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Cytotoxic T cells; HLA A2 restricted; HLA A2 Kb transgenic mice; In vivo protection; Influenza; Matrix protein

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; INFLUENZA MATRIX PROTEIN EPITOPE[58-66]; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; LUNG; LYMPHOCYTE DEPLETION; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE; TRANSGENIC MOUSE; VIRUS IMMUNITY;

MUS MUSCULUS;

EID: 0037903332     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00072-2     Document Type: Article

References (56)

1. Bachmann M.F., Ecabert B., Kroft M. Influenza virus a novel method to assess viral and neutralizing antibody titers in vitro . J. Immunol. Methods. 225:1999;105-111.
2. Beck A., Bussat M.C., Klinguer-Hamour C., Goetsch L., Aubry J.P., Champion T., Julien E., Haeuw J.F., Bonnefoy J.Y., Corvaia N. Stability and CTL activity of N-terminal glutamic acid containing peptides. J. Pept. Res. 57:2001;528-538.
3. Belz G.T., Stevenson P.G., Doherty P.C. Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza viruses. J. Immunol. 165:2000;2404-2409.
4. Bender B.S., Small P.A. Jr. Influenza pathogenesis and host defense . Semin. Respir. Infect. 7:1992;38-45.
5. BenMohamed L., Krishnan R., Longmate J., Auge C., Low L., Primus Diamond D.J. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice dependence on HLA class II restricted T(H) response . Hum. Immunol. 61:2000;764-777.
6. Bharadwaj B., Sherritt M., Khanna R., Moss D.J. Contrasting Epstein-Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice implications for vaccine design . Vaccine. 19:2001;3769-3777.
7. Bjorkman P.J., Saper M.A., Samaraoui B., Bennett W.S., Strominger J.L., Wiley D.C. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 329:1987;506-512.
8. Bot A., Casares S., Bot S., von Boehemer H., Bona C. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells. J. Immunol. 160:1998;4500-4507.
9. Bot A., Stan A.C., Inaba K., Steinman R., Bona C. Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class-I-restricted cytotoxic lymphocytes upon adoptive transfer. Int. Immunol. 12:2000;825-832.
10. Carman W.F., Elder A.G., Wallace L.A., McAulay K., Walker A., Murray G.D., Stott D.J. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care a randomised controlled trial . Lancet. 355:2000;93-97.
11. Cerwenka A., Morgan T.M., Dutton R.W. Naive, effector, and memory CD8 T cells in protection against pulmonary virus infection homing properties rather than initial frequencies are crucial . J. Immunol. 163:1999;5535-5543.
12. Cerwenka A., Morgan T.M., Harmsen A.G., Dutton R.W. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J. Exp. Med. 189:1999;423-434.
13. Diethelm-Okita B.M., Okita D.K., Banaszak L., Conti-Fine B.M. Universal epitopes for human CD4+ cells on Tetanus and Diphteria toxins. J. Infect. Dis. 181:2000;1001-1009.
14. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D. Jr., Palmer S.P., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169:1994;68-76.
15. Eichelberger M., Allan W., Zijlstra M., Jaenisch R., Doherty P.C. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J. Exp. Med. 174:1991;875-880.
16. Engelhard V.H., Lacy E., Ridge J.P. Influenza-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J. Immunol. 146:1991;1226-1232.
17. Epstein S.L., Stack A., Misplon J.A., Lo C.Y., Mostowski H., Bennink J., Subbarao K. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8+ cytotoxic T lymphocytes either CD4+ or CD8+ T cells can promote survival and recovery after challenge . Int. Immunol. 12:2000;91-101.
18. Falsey A.R., Cunningham C.K., Barker W.H., Kouides R.W., Yuen J.B., Menegus M., Weiner L.B., Bonville C.A., Betts R.F. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:1995;389-394.
19. Fernando G.J., Khammanivong V., Leggatt G.R., Liu W.J., Frazer I.H. The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial non-specific stimulation. Eur. J. Immunol. 32:2002;1541-1544.
20. Flynn K.J., Belz G.T., Altman J.D., Ahmed R., Wood D.L., Doherty P.C. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity. 8:1998;683-691.
21. Flynn K.J., Riberdy J.M., Christensen J.P., Altman J.D., Doherty P.C. In vivo proliferation of naive and memory influenza-specific CD8+ T cells. Proc. Natl. Acad. Sci. USA. 96:1999;8597-8602.
22. Fomsgaard A., Nielsen H.V., Kirkby N., Bryder K., Corbet S., Nielsen C., Hinkula J., Buus S. Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes. Vaccine. 18:1999;681-691.
23. Gianfrani C., Oseroff C., Sidney J., Chesnut R.W., Sette A. Human memory CTL response specific for Influenza A virus is broad and multispecific. Hum. Immunol. 61:2000;438-452.
24. Gotch F.M., McMichael A.J., Smith G., Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 165:1987;408-416.
25. Gotch F.M., Rothbard J.B., Howland K., Townsend A.R., McMichael A.J. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature. 326:1987;881-882.
26. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons. Ann. Intern. Med. 123:1995;518-527.
27. Hogan R.J., Usherwood E.J., Zhong W., Roberts A.A., Dutton R.W., Harmsen A.G., Woodland D.L. Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166:2001;1813-1822.
28. Jameson J., Cruz J., Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 72:1998;8682-8689.
29. Keogh E., Fikes J., Southwood S., Celis E., Chesnut R., Sette A. Identification of new epitopes from four different tumor-associated antigens recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity . J. Immunol. 167:2001;787-796.
30. Kilbourne E.D., Johansson B.E., Grajowe B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad. Sci. USA. 87:1990;786-790.
31. Kuwano K., Scott M., Young J., Ennis F.A. Active immunization against virus infections due to antigenic drift by induction of cross-reactive cytotoxic T lymphocytes. J. Exp. Med. 169:1989;1361-1371.
32. La Gal F.A., Prevost-Blondel A., Lengagne R., Bossus M., Farace F., Chaboissier A., Gras-Masse H., Engelhard V.H., Guillet J.G., Gahery-Segard H. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinical study. Int. J. Cancer. 98:2002;221-227.
33. Laver W.G., Gerhard W., Webster R.G., Frankel M.E., Air G.M. Antigenic drift in type A influenza virus peptide mapping and antigenic analysis of A/PR/8/34 (H1N1) variants selected with monoclonal antibodies . Proc. Natl. Acad. Sci. USA. 76:1979;1425-1429.
34. Levy E. French economic evaluation of influenza and influenza vaccination. Pharmacoeconomics. 9:(S3):1996;73-74.
35. Linnemann T., Jung G., Walden P. Detection and quantification of CD4+ T cells with specificity for a new major histocompatibility complex class II-restricted influenza A virus matrix protein epitope in peripheral blood of influenza patients. J. Virol. 74:2000;8740-8743.
36. MacKenzie C.D., Taylor P.M., Askonas B.A. Rapid recovery of lung histology correlates with clearance of influenza virus specific CD8+ cytotoxic T cells. Immunology. 67:1989;375-381.
37. Man S., Newberg M.H., Crotzer V.L., Luckey C.J., Williams N.S., Chen Y., Huczko E.L., Ridge J.P., Engelhard V.H. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A.1 transgenic mice. Int. Immunol. 7:1995;597-605.
38. Moss B.A., Underwood P.A., Bender V.J., Whittaker R.G. Antigenic drift in the hemagglutinin from various strains of influenza virus A/Hong-Kong/68 (H3N2). Laver W.G., Air G.M. Structure and Variation in Influenza Virus. 1980;329 Elsevier/North-Holland, Amsterdam, The Netherlands.
39. Ostankovitch M., Le Gal F.A., Connan F., Chassin D., Choppin J., Guill J.G. Generation of Melan-A/Mart-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors helper effect requirement for efficient primary cytotoxic T lymphocytes in vitro . Int. J. Cancer. 17:1997;987-994.
40. Plotnicky-Gilquin H., Huss T., Aubry J.P., Haeuw J.F., Beck A., Bonnefoy J.Y., Nguyen T.N., Power U.F. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology. 258:1999;128-140.
41. Plotnicky-Gilquin H., Robert A., Chevalet L., Haeuw J.F., Beck A., Bonnefoy J.Y., Brandt C., Siegrist C.A., Nguyen T.N., Power U.F. CD4+ T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment. J. Virol. 74:2000;3455-3463.
42. Potter J., Stott D.J., Roberts M.A., Elder A.G., O'Donnelle B., Knight P.V., Carman W.F. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J. Infect. Dis. 175:1997;1-6.
43. Power U.F., Plotnicky-Gilquin H., Huss T., Robert A., Trudel M., Stahl S., Uhlen M., Nguyen T.N., Binz H. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 230:1997;155-166.
44. Rivoltini L., Squarcina P., Loftus D.J., Castelli C., Tarsini P., Mazzocchi A., Rini F., Viggiano V., Belli F., Parmiani G. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-meloma CD8+ T cells with enhanced functional characteristics implication for more effective immunotherapy . Cancer Res. 59:1999;301-306.
45. Robbins P.A., Rota P.A., Shapiro S.Z. A broad cytotoxic response to influenza type B virus presented by multiple HLA molecules. Int. Immunol. 9:1997;815-823.
46. Sambhara S., Kurichh A., Miranda R., Tumpey T., Rowe T., Renshaw M., Arpino R., Tamane A., Kandil A., James O., Underdown B., Klein M., Katz J., Burt D. Heterosubtypic immunity against human influenza A viruses including recently emerged avian H5 and H9 viruses, induced by Flu-ISCOM vaccine in mice requires both cytotoxic T-lymphocytes and macrophage function. Cell. Immunol. 211:2001;143-153.
47. Sherman L.A., Hesse S.V., Irwin M.J., La Face D., Peterson P. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science. 258:1992;815-818.
48. Townsend A.R.M., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 44:1986;959-968.
49. Valmori D., Pessi A., Bianchi E., Corradin G. Use of human universally antigenic tetanus toxin T cell epitope as carriers for human vaccination. J. Immunol. 149:1992;717-721.
50. Valmori D., Romero J.F., Men Y., Maryanski J.L., Romero P., Corradin G. Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA) further enhancement by pre-injection of IFA alone . Eur. J. Immunol. 24:1994;1458-1462.
51. Vitiello A., Marchesini D., Furze J., Sherman L.A., Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1991;1007-1015.
52. Wells M.A., Albrecht P., Ennis F.A. Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. J. Immunol. 126:1981;1036-1041.
53. Weninger W., Crowley M.A., Manjunath N., von Andrian U.H. Migratory properties of naive, effector, and memory CD8(+) cells. J. Exp. Med. 194:2001;953-966.
54. Whitton J.L., Oldstone M.B.A. The immune response to viruses. Fields B.N., Knipe D.M., Howley P.M. Fields' Virology. 3rd ed:1996;345-374 Raven Press, New York.
55. Yewdell J.W., Bennink J.R. Immunodominance in MHC class-I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:1999;51-88.
56. Zhou H.C., Xu D.Z., Wang X.P., Zhang J.X., Huang Y., Yan Y.P., Zhu Y., Jin B.Q. Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes. World J. Gastroenterol. 7:2001;583-586.